<DOC>
	<DOC>NCT01858766</DOC>
	<brief_summary>The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV) in treatment-naive adults with chronic genotype (GT) 1, 2, 3, 4, 5, or 6 hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Chronic HCV infection Body mass index (BMI) ≥ 18 kg/m^2 HCV RNA ≥ 10000 IU/mL at screening Use of highly effective contraception methods if female of childbearing potential or sexually active male Must not have cirrhosis Current or prior history of clinically significant illness other than HCV Screening ECG with clinically significant abnormalities Prior exposure to HCV specific direct acting antiviral agent Prior treatment of HCV with interferon or ribavirin Pregnant or nursing female or male with pregnant female partner Chronic liver disease of nonHCV etiology Hepatitis B Active drug abuse Use of any prohibited concomitant medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>HCV Genotype 1</keyword>
	<keyword>HCV Genotype 2</keyword>
	<keyword>HCV Genotype 3</keyword>
	<keyword>HCV Genotype 4</keyword>
	<keyword>HCV Genotype 5</keyword>
	<keyword>HCV Genotype 6</keyword>
	<keyword>treatment naive</keyword>
</DOC>